Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 37c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($0.32), $0.37 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $49.56 million versus the consensus estimate of $14.8 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Worthington Industries (WOR) Misses Q4 EPS by 9c